New decision aid could boost use of IUDs for cancer prevention

NCT ID NCT07382583

Recruiting now Prevention Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study aims to create an educational tool that helps women and their doctors make informed choices about using a levonorgestrel-releasing intrauterine system (LNG-IUS) to prevent endometrial cancer. Researchers will survey 270 women, both with and without a history of the disease, to understand their preferences. The goal is to improve shared decision-making and increase uptake of this prevention option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: levonorgestrel-releasing intrauterine system (LNG-IUS)
What this could lead to: If successful, this tool could help more women choose an effective option to prevent endometrial cancer, potentially reducing cases.
What could go wrong: This is an early-stage study focused on developing a decision tool, not testing the IUD itself. The tool may not change actual prevention rates or be widely adopted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMPLEX ATYPICAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

complex endometrial hyperplasia endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER INTRAUTERINE SYSTEMS LEVONORGESTREL PREVENTION

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
The Harris Health System (LBJ)
RECRUITING

Houston, Texas, 77026, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.